Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
The enterprise value (EV) is $120.04M.
ENTERPRISE VALUE (EV)
$120.04M
X4 Pharmaceuticals, Inc.
Market Cap
$260.79M
Enterprise Value (EV)
$120.04M
| NAME | MARKET CAP | ENTERPRISE VALUE (EV) |
|---|---|---|
| X4 Pharmaceuticals, Inc. (XFOR) | $260.79M | $120.04M |
| Lexeo Therapeutics, Inc. Common Stock (LXEO)vs › | $261.48M | $175.45M |
| OraSure Technologies, Inc. (OSUR)vs › | $261.97M | $113.48M |
| Palisade Bio, Inc. (PALI)vs › | $262.04M | $136.86M |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $262.81M | $212.32M |
| AC Immune S.A. (ACIU)vs › | $257.65M | $228.39M |
| Inhibikase Therapeutics, Inc. (IKT)vs › | $264.74M | $233.53M |
| Anika Therapeutics, Inc. (ANIK)vs › | $256.69M | $241.59M |
| EyePoint Pharmaceuticals, Inc. (EYPT)vs › | $264.94M | $176.85M |
| Treace Medical Concepts, Inc. (TMCI)vs › | $267.93M | $328.01M |
Market Cap
$260.79M
Total Debt
$76.29M
Cash
$217.05M
Enterprise Value
$120.04M
Why use EV instead of Market Cap?
Enterprise Value represents the total value of a company as if you were to acquire it completely - paying for equity while assuming debt and receiving cash.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
